[A20-91] Bempedoic acid/ezetimibe (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V

Last updated 01.02.2021

Project no.:

Commission awarded on 30.10.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia

Result of dossier assessment:

Added benefit not proven in either of both research questions (drug and dietary lipid-lowering options not exhausted/exhausted except for evolocumab)


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relvant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form